Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVA: Gardasil 9 for Anal and Vulvar Neoplasia
NCT03051516Phase 4Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2017
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in anal intraepithelial neoplasia (AIN) and vulvar intraepithelial neoplasia (VIN) comparing Gardasil 9 with Placebo (2 arms). Primary endpoint: Persistent High-risk Infection Among Vaccine Compared With Placebo Recipients at 36 months. Started Aug 2017; status: terminated.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
anal intraepithelial neoplasia (AIN)vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NCT03051516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051516.